BIOMAT Database Logo BIOMAT Database Logo

Prognostic value of loss of heterozygosity at BRCA2 in human breast carcinoma. 1997

I Bièche, and C Noguès, and S Rivoilan, and A Khodja, and A Latil, and R Lidereau
Laboratoire d'Oncogénétique, Centre René Huguenin, St-Cloud, France.

To confirm several recent studies pointing to loss of heterozygosity (LOH) at BRCA2 as a prognostic factor in sporadic breast cancer, we examined this genetic alteration in a large series of human primary breast tumours for which long-term patient outcomes were known. LOH at BRCA2 correlated only with low oestrogen and progesterone receptor content. Univariate analysis of metastasis-free survival and overall survival (log-rank test) showed no link with BRCA2 status (P = 0.34, P = 0.29 respectively). LOH at BRCA2 does not therefore appear to be a major prognostic marker in sporadic breast cancer.

UI MeSH Term Description Entries
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA
D005260 Female Females
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

I Bièche, and C Noguès, and S Rivoilan, and A Khodja, and A Latil, and R Lidereau
Loss of heterozygosity at 13q13 and 14q32 predicts BRCA2 inactivation in luminal breast carcinomas.
December 2013, International journal of cancer,
I Bièche, and C Noguès, and S Rivoilan, and A Khodja, and A Latil, and R Lidereau
Loss of heterozygosity of BRCA1, BRCA2 and ATM genes in sporadic invasive ductal breast carcinoma.
October 1998, International journal of oncology,
I Bièche, and C Noguès, and S Rivoilan, and A Khodja, and A Latil, and R Lidereau
Loss of heterozygosity at BRCA2 in a ductal carcinoma in situ and three invasive breast carcinomas in a family with a germline BRCA2 mutation.
October 2004, Breast cancer research and treatment,
I Bièche, and C Noguès, and S Rivoilan, and A Khodja, and A Latil, and R Lidereau
Improved detection of loss of heterozygosity at retinoblastoma gene locus in human breast carcinoma.
January 1994, Pathology international,
I Bièche, and C Noguès, and S Rivoilan, and A Khodja, and A Latil, and R Lidereau
[Prognostic value of heterozygosity loss in chromosome 3p in non-microcytic bronchogenic carcinoma].
April 1999, Medicina clinica,
I Bièche, and C Noguès, and S Rivoilan, and A Khodja, and A Latil, and R Lidereau
Loss of heterozygosity in sporadic breast tumours at the BRCA2 locus on chromosome 13q12-q13.
November 1995, British journal of cancer,
I Bièche, and C Noguès, and S Rivoilan, and A Khodja, and A Latil, and R Lidereau
Allelic loss at the BRCA1, BRCA2 and TP53 loci in human sporadic breast carcinoma.
March 2000, Cancer letters,
I Bièche, and C Noguès, and S Rivoilan, and A Khodja, and A Latil, and R Lidereau
Loss of heterozygosity at chromosome 1p in human breast cancer.
October 1996, International journal of oncology,
I Bièche, and C Noguès, and S Rivoilan, and A Khodja, and A Latil, and R Lidereau
High incidence of loss of heterozygosity at chromosome 17p13 in breast tumours from BRCA2 mutation carriers.
January 1998, Oncogene,
I Bièche, and C Noguès, and S Rivoilan, and A Khodja, and A Latil, and R Lidereau
Sporadic breast cancer in young women: prevalence of loss of heterozygosity at p53, BRCA1 and BRCA2.
March 2002, International journal of cancer,
Copied contents to your clipboard!